[go: up one dir, main page]

BRPI0816554A2 - compostos como antagonistas de receptores de adenosina a1. - Google Patents

compostos como antagonistas de receptores de adenosina a1.

Info

Publication number
BRPI0816554A2
BRPI0816554A2 BRPI0816554A BRPI0816554A BRPI0816554A2 BR PI0816554 A2 BRPI0816554 A2 BR PI0816554A2 BR PI0816554 A BRPI0816554 A BR PI0816554A BR PI0816554 A BRPI0816554 A BR PI0816554A BR PI0816554 A2 BRPI0816554 A2 BR PI0816554A2
Authority
BR
Brazil
Prior art keywords
compounds
receptor antagonists
adenosine receptor
adenosine
antagonists
Prior art date
Application number
BRPI0816554A
Other languages
English (en)
Inventor
Juan Alberto Camacho Gomez
Lyhen Gonzaez Lio
Original Assignee
Palobiofarma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Palobiofarma Sl filed Critical Palobiofarma Sl
Publication of BRPI0816554A2 publication Critical patent/BRPI0816554A2/pt
Publication of BRPI0816554B1 publication Critical patent/BRPI0816554B1/pt
Publication of BRPI0816554B8 publication Critical patent/BRPI0816554B8/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
BRPI0816554A 2007-10-02 2008-09-30 compostos como antagonistas de receptores de adenosina a1 BRPI0816554B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200702643 2007-10-02
ES200702643A ES2331220B1 (es) 2007-10-02 2007-10-02 Nuevos compuestos como antagonistas de los receptores a1 de adenosina.
PCT/IB2008/002556 WO2009044250A1 (en) 2007-10-02 2008-09-30 New compounds as adenosine a1 receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0816554A2 true BRPI0816554A2 (pt) 2015-11-24
BRPI0816554B1 BRPI0816554B1 (pt) 2019-04-09
BRPI0816554B8 BRPI0816554B8 (pt) 2022-08-30

Family

ID=40303525

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816554A BRPI0816554B8 (pt) 2007-10-02 2008-09-30 compostos como antagonistas de receptores de adenosina a1

Country Status (20)

Country Link
US (1) US8410282B2 (pt)
EP (1) EP2197860B1 (pt)
JP (1) JP5463592B2 (pt)
KR (1) KR101312198B1 (pt)
CN (1) CN101835766B (pt)
AT (1) ATE510829T1 (pt)
AU (1) AU2008306553B2 (pt)
BR (1) BRPI0816554B8 (pt)
CA (1) CA2700526C (pt)
CY (1) CY1112079T1 (pt)
DK (1) DK2197860T3 (pt)
EA (1) EA022473B1 (pt)
ES (2) ES2331220B1 (pt)
HR (1) HRP20110557T1 (pt)
MX (1) MX2010003576A (pt)
PL (1) PL2197860T3 (pt)
PT (1) PT2197860E (pt)
SI (1) SI2197860T1 (pt)
WO (1) WO2009044250A1 (pt)
ZA (1) ZA201002139B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076734A1 (en) * 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2014106861A1 (en) * 2013-01-03 2014-07-10 Council Of Scientific & Industrial Research (4e)-4-(4-substituted benzylideneamino)-2,3-dihydro-3- substituted-2-thioxothiazole-5-carbonitriles as a2ar antagonist and process for preparation thereof
JP6434968B2 (ja) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としての三環式ピリド−カルボキサミド誘導体
JP6522602B2 (ja) 2013-07-02 2019-05-29 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Rock阻害剤としての三環式ピリド−カルボキサミド誘導体
ES2578363B1 (es) 2015-01-22 2017-01-31 Palobiofarma, S.L. Moduladores de los receptores A3 de adenosina
ES2676535B1 (es) * 2017-01-20 2019-04-29 Palobiofarma Sl Moduladores de los receptores a3 de adenosina
LT3592734T (lt) 2017-03-06 2021-07-26 Palobiofarma, S.L. (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska
CN107739350B (zh) * 2017-09-26 2020-12-22 天津大学 一种合成2-氨基噻唑衍生物的方法
BR112021004999A2 (pt) 2018-09-17 2021-06-08 Yungjin Pharm. Co., Ltd. composto e método de inibição de cdk7 em um sujeito
EP3882240A1 (en) * 2020-03-16 2021-09-22 Palobiofarma, S.L. Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid
EP3957308A1 (en) * 2020-08-21 2022-02-23 Palobiofarma, S.L. (1r,3s)-3-((5-cyano-4-phenylthiazol-2-yl)carbamoyl)cyclopentane-1-carboxylic acid and derivatives thereof for use in the treatment of airway diseases
CN119039300A (zh) * 2024-08-29 2024-11-29 上海信诺维生物医药有限公司 吡唑并嘧啶类化合物的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050004134A1 (en) * 2001-11-08 2005-01-06 Hideo Tsutsumi Thiazole derivative and pharmaceutical use thereof
KR101010905B1 (ko) * 2002-01-18 2011-01-25 아스텔라스세이야쿠 가부시키가이샤 2-아실아미노티아졸 유도체 또는 그 염
NZ570835A (en) * 2006-03-08 2011-11-25 Achillion Pharmaceuticals Inc Substituted aminothiazole derivatives with anti-HCV activity
WO2007116106A1 (es) * 2006-04-12 2007-10-18 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina

Also Published As

Publication number Publication date
AU2008306553A1 (en) 2009-04-09
PL2197860T3 (pl) 2011-09-30
PT2197860E (pt) 2011-08-26
EP2197860B1 (en) 2011-05-25
KR101312198B1 (ko) 2013-09-27
BRPI0816554B8 (pt) 2022-08-30
AU2008306553B2 (en) 2011-06-09
CN101835766A (zh) 2010-09-15
ZA201002139B (en) 2011-06-29
EA201000393A1 (ru) 2010-08-30
BRPI0816554B1 (pt) 2019-04-09
CA2700526A1 (en) 2009-04-09
ES2331220A1 (es) 2009-12-23
JP2010540615A (ja) 2010-12-24
US20100311703A1 (en) 2010-12-09
ES2331220B1 (es) 2010-09-23
WO2009044250A1 (en) 2009-04-09
DK2197860T3 (da) 2011-08-15
US8410282B2 (en) 2013-04-02
JP5463592B2 (ja) 2014-04-09
HRP20110557T1 (hr) 2011-09-30
CN101835766B (zh) 2013-09-25
ES2366075T3 (es) 2011-10-17
SI2197860T1 (sl) 2011-09-30
EA022473B1 (ru) 2016-01-29
EP2197860A1 (en) 2010-06-23
ATE510829T1 (de) 2011-06-15
MX2010003576A (es) 2010-04-22
KR20100058653A (ko) 2010-06-03
CY1112079T1 (el) 2015-11-04
CA2700526C (en) 2014-03-18

Similar Documents

Publication Publication Date Title
BRPI0816554A2 (pt) compostos como antagonistas de receptores de adenosina a1.
BRPI0909157A2 (pt) compostos heterocíclicos como antagonistas de receptores de adenosina
BRPI0716936A2 (pt) derivados de adenosina como antigonistas de receptor de a2a
CR10249A (es) Compuestos de amino- pirimidina 2,6-sistituidos -4-monosustituidos como antagonistas del receptor de prostaglandina d2
EP2350060A4 (en) Melanocortin receptor AGONISTS
BRPI0821141A2 (pt) Derivados de heteroarila como antagonistas do receptor de orexina
BRPI0911542A2 (pt) compostos de quinuclina como ligantes de receptor de receptor de acetilcolina alfa-7-nicotínica
BRPI0717937A2 (pt) Compostos de pirazona como antagonistas do receptor mineralocorticóide
BRPI0717023A2 (pt) Tiazol pirazolopirimidina como antagonistas do receptor de crf1
BRPI0818578A2 (pt) Derivados de purina como ligantes receptores de adenosina a1
DK2089382T3 (da) Substituerede diazepan-forbindelser som orexin-receptor-antagonister
BRPI0913930A2 (pt) antagonistas de receptores de prostaglandinas d2
BRPI0810462A2 (pt) Derivados de quinolina-carboxamida como antagonistas de p2y12
EP2349270A4 (en) 2,5-DISUBSTITUTED PIPERIDINOREXINE RECEPTOR ANTAGONISTS
BRPI0813768A2 (pt) Derivados de benzazepina úteis como antagonistas de vasopressina
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
BRPI0919844A2 (pt) compostos de azaindazol como antagonistas do receptor ccr1
BRPI0815797A2 (pt) Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu
BRPI0820805A2 (pt) Antagonista do receptor de mineralocorticóides derivados da 6h-di-benzo[b,e]oxepina
BRPI0817061A2 (pt) Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
BRPI0814806A2 (pt) Pirazinas substituídas como antagonistas de cb1
EP2379510A4 (en) quinazolinone
BRPI0720078A2 (pt) 2-aminoquinolinas como antagonistas de receptores de 5-ht(5a)
BRPI0814767A2 (pt) Derivados de monoamida como antagonistas do receptor de orexina
BRPI0809641A2 (pt) Pirimidinil-piperazinas úteis como ligantes do receptor d3/d2hu

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/09/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2518 DE 09/04/2019 QUANTO AO INVENTOR.